The Usefulness of a Percutaneous Cardiopulmonary Support Device for the Treatment of Fulminant Myocarditis.
- Author:
Juyong LIM
1
;
Sung Ho JUNG
;
Hyoung Gon JE
;
Taek Yeon LEE
;
Suk Jung CHOO
;
Jae Won LEE
;
Cheol Hyun CHUNG
Author Information
1. Department of Thoracic and Cardiovascular Sugery, Seoul Asan Hospital, University of Ulsan College of Medicine, Korea. hyun227@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Myocarditis;
Heart assist device;
Heart transplantation;
Cardiogenic shock
- MeSH:
Arrhythmias, Cardiac;
Cardiomyopathy, Dilated;
Echocardiography;
Emergencies;
Heart;
Heart Transplantation;
Humans;
Myocarditis;
Prognosis;
Retrospective Studies;
Running;
Shock, Cardiogenic;
Stroke Volume;
Tokyo;
Transplants;
Ventricular Dysfunction, Left
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2010;43(1):20-24
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Fulminant myocarditis is a rare, but life threatening condition. Its prognosis is related with proper management in the acute phase. A cardiopulmonary support device can be very useful in this phase. We report on our experiences with managing acute fulminant myocarditis with a cardiopulmonary support (CPS) device. MATERIAL AND METHOD: We reviewed retrospectively 9 patients who had a CPS device used for their fulminant myocarditis between September, 2006 and October, 2008. A Capiox emergency bypass system (Terumo Inc, Tokyo, Japan) was percutaneously inserted in all the patients. Upon implantation, all the patients were in cardiogenic shock because of ventricular arrhythmia or severe left ventricular dysfunction. The mean left ventricular ejection fraction (EF) was 20+/-6% according to transthoracic echocardiography. RESULT: 3 patients died despite CPS. The CPS was bridged to a transplanted heart in one patient. The rest were successfully explanted after a mean time of 107+/-70 hours of running. The mean EF after discharge was 56+/-7% without dilated cardiomyopathy. CONCLUSION: Fulminant myocarditis can be fatal, but its prognosis is excellent if these patients receive proper, timely treatment. A cardiopulmonary support device can be very useful in this acute period. However, the implantation and management protocol of cardiopulmonary support are not yet settled. Further study is necessary to lower the complications of cardiopulmonary support for patients with fulminant myocarditis.
